Taking into account that loss of Naa40 has no effect on cell viability of noncancerous embryonic fibroblasts, the present study identifies Naa40 inhibition as a potential epigenetic therapeutic strategy, which could be used in the treatment of colon cancers carrying either wild-type or mutant p53. This evidence concerns the gene NAA40 and colonic neoplasm.